Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure

116
13
Favorite

Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure

Seeking Alpha2022-02-03

The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.
The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.
The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.
The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.
CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.
BCDA +29.94% premarket to $2.04

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

116

Report

Comment（13）

Mm101
·2022-02-06
Ff
Reply
1
Report
potato112
·2022-02-04
Yay, like please. Tq! 😁
Reply
2
Report
EHG
·2022-02-04
Like
Reply
1
Report
jason90
·2022-02-03
Ok
Reply
3
Report
KelvinChan
·2022-02-03
Ok
Reply
5
Report
JeffTai
·2022-02-03
Ok
Reply
5
Report
Bonghanhuei
·2022-02-03
Ok
Reply
4
Report
咩咩虎
·2022-02-03
Ok
Reply
6
Report
Nagoken
·2022-02-03
Gello
Reply
2
Report
Zhaoxiang
·2022-02-03
Damn
Reply
3
Report
mko2
·2022-02-03
This is the future
Reply
4
Report
BBBBBBBBBB
·2022-02-03
K
Reply
2
Report
sibeichio
·2022-02-03
Wa that's really good
Reply
2
Report

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-03 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196144953","market":"us","top_or_hot":-1,"title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","media":"Seeking Alpha","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCDA","symbol_name":"BioCardia","start_time":0,"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","article_id":"1196144953","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","pubTimestamp":1643896451,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCDA":"BioCardia"},"translate_title":"Biocardia在FDA突破性设备标签上上涨30%用于心力衰竭的心律失常系统","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCDA":0.9},"content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":9098272543,"gmtCreate":1644162828644,"gmtModify":1676533895535,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3565081661382277","idStr":"3565081661382277"},"htmlText":"Ff","listText":"Ff","text":"Ff","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098272543","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091464520,"gmtCreate":1643932004610,"gmtModify":1676533872306,"author":{"id":"4101534862379370","authorId":"4101534862379370","name":"potato112","avatar":"https://static.itradeup.com/news/c979f6cdb3624170ce5e74ecfed3c464","vip":1,"crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"4101534862379370","idStr":"4101534862379370"},"htmlText":"Yay, like please. Tq! 😁","listText":"Yay, like please. Tq! 😁","text":"Yay, like please. Tq! 😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091464520","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091415034,"gmtCreate":1643930260318,"gmtModify":1676533871706,"author":{"id":"3586941861951066","authorId":"3586941861951066","name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3586941861951066","idStr":"3586941861951066"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091415034","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091520249,"gmtCreate":1643901786091,"gmtModify":1676533869736,"author":{"id":"3585175001551527","authorId":"3585175001551527","name":"jason90","avatar":"https://static.tigerbbs.com/c05971f1eb947b3bc72b4716947fc063","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3585175001551527","idStr":"3585175001551527"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091520249","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091586911,"gmtCreate":1643899737416,"gmtModify":1676533869349,"author":{"id":"3570776252336545","authorId":"3570776252336545","name":"KelvinChan","avatar":"https://static.tigerbbs.com/322f5dea7567e161ddef26aec462d83d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3570776252336545","idStr":"3570776252336545"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091586911","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091581699,"gmtCreate":1643899584627,"gmtModify":1676533869309,"author":{"id":"3581504334066898","authorId":"3581504334066898","name":"JeffTai","avatar":"https://static.tigerbbs.com/eaf357935d6e8ef3744f3d94312f0a64","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581504334066898","idStr":"3581504334066898"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091581699","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091581863,"gmtCreate":1643899582218,"gmtModify":1676533869341,"author":{"id":"3581734044994294","authorId":"3581734044994294","name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581734044994294","idStr":"3581734044994294"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091581863","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091518733,"gmtCreate":1643898754408,"gmtModify":1676533869058,"author":{"id":"3568542354994015","authorId":"3568542354994015","name":"咩咩虎","avatar":"https://static.tigerbbs.com/a6663bef57eca539a2c52ea184964654","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3568542354994015","idStr":"3568542354994015"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091518733","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091518070,"gmtCreate":1643898625381,"gmtModify":1676533869028,"author":{"id":"3576560237263785","authorId":"3576560237263785","name":"Nagoken","avatar":"https://static.tigerbbs.com/caac3ac5db4b0d37985b9f55a62d569f","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3576560237263785","idStr":"3576560237263785"},"htmlText":"Gello","listText":"Gello","text":"Gello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091518070","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091511439,"gmtCreate":1643898566074,"gmtModify":1676533869012,"author":{"id":"3573361937273706","authorId":"3573361937273706","name":"Zhaoxiang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3573361937273706","idStr":"3573361937273706"},"htmlText":"Damn","listText":"Damn","text":"Damn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091511439","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091513403,"gmtCreate":1643898349602,"gmtModify":1676533868988,"author":{"id":"4088161478987360","authorId":"4088161478987360","name":"mko2","avatar":"https://static.tigerbbs.com/97227b08b73f92dfa3c97c435e1a0345","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"4088161478987360","idStr":"4088161478987360"},"htmlText":"This is the future","listText":"This is the future","text":"This is the future","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091513403","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091513957,"gmtCreate":1643898299704,"gmtModify":1676533868973,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581562365927542","idStr":"3581562365927542"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091513957","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091538745,"gmtCreate":1643896950921,"gmtModify":1676533868805,"author":{"id":"3577833998057162","authorId":"3577833998057162","name":"sibeichio","avatar":"https://static.tigerbbs.com/23a89e5b42d7f3dbef81994ec91df774","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3577833998057162","idStr":"3577833998057162"},"htmlText":"Wa that's really good","listText":"Wa that's really good","text":"Wa that's really good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091538745","repostId":1196144953,"repostType":4,"repost":{"id":"1196144953","kind":"news","pubTimestamp":1643896451,"share":"https://ttm.financial/m/news/1196144953?lang=en_US&edition=fundamental","pubTime":"2022-02-03 21:54","market":"us","language":"en","title":"Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1196144953","media":"Seeking Alpha","summary":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NA","content":"<html><head></head><body><ul><li>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia&#39;s(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.</li><li>The company said it is believed to be the first cardiac cell therapy to receive the FDA&#39;s breakthrough device status.</li><li>The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.</li><li>The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.</li><li>CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.</li><li>BCDA +29.94% premarket to $2.04</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocardia Rises 30% on FDA Breakthrough Device Tag for Cardiamp System for Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BCDA":"BioCardia"},"source_url":"https://seekingalpha.com/news/3795517-biocardia-rises-30-on-fda-breakthrough-device-tag-for-cardiamp-system-for-heart-failure","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196144953","content_text":"The U.S. Food and Drug Administration (FDA)granted breakthrough device designation to BioCardia's(NASDAQ:BCDA)CardiAMP Cell Therapy System to treat heart failure.The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status.The CardiAMP Cell Therapy Heart Failure Trial in the U.S. is currently enrolling patients to evaluate the effectiveness of the system in improving survival, reducing major adverse cardiac events, enhancing functional capacity, and improving quality of life for patients.The company said the system has shown no incidence of mortality at one year in its phase 2 trial or in the 10-patient roll-in cohort from the phase 3 trial that is currently enrolling.CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure.BCDA +29.94% premarket to $2.04","news_type":1,"symbols_score_info":{"BCDA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":116,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}